睾酮(Testosterone) - 药物靶点：AR_在研适应症：低睾酮水平，睾酮缺乏，性腺机能减退_专利_临床

概要

基本信息

药物类型

小分子化药

别名

17beta-hydroxy-4-androsten-3-one、4-androsten-17β-ol-3-one、Testosterone (JAN/USP)

+ [35]

靶点

AR

作用机制

AR激动剂(雄激素受体激动剂)

治疗领域

内分泌与代谢疾病

在研适应症

低睾酮水平睾酮缺乏性腺机能减退+ [1]

非在研适应症

阿尔茨海默症雄激素缺乏症雄激素不敏感综合征+ [34]

原研机构

AbbVie, Inc.

在研机构

Endo Operations Ltd.Besins Healthcare (UK) Ltd.

Halozyme Therapeutics, Inc.

+ [5]

非在研机构

Bayer AG

AbbVie, Inc.

National Institute on Aging

+ [17]

最高研发阶段批准上市

首次获批日期

美国 (1995-09-29),

性腺机能减退

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)

登录后查看时间轴

结构

分子式C19H28O2

InChIKeyMUMGGOZAMZWBJJ-DYKIIFRCSA-N

CAS号58-22-0

关联

445

项与睾酮相关的临床试验

NCT01894308 / Not yet recruiting临床2期

A Multiple-Dose, Single Period, Phase II Dose Ranging Study to Examine TDS-Testosterone 5% in Adult Male Subjects

This study is a continuation of previous studies done in healthy volunteers to prove the efficacy of delivering Testosterone, the male hormone, rapidly across intact skin in s series of doses from low to high in men with low-to-no natural testosterone production to measure their response to the varying doses. The results of this study will inform further studies which will be longer in length, as to the starting doses. The study will be conducted in London, U.K. at the Advanced Therapies Centre, The London Clinic.

开始日期2025-06-01

申办/合作机构

Transdermal Delivery Solutions Corp.

NCT06733350 / Not yet recruiting临床4期IIT

Investigating the Effect of Testosterone Replacement Therapy Among Hypogonadal Men With Localized Prostate Cancer on Active Surveillance

This phase IV trial studies the effects of testosterone replacement therapy (TRT) on treatment outcomes in hypogonadal men with prostate cancer that has not spread to other parts of the body (localized) and who are on active surveillance (AS). AS in prostate cancer involves closely watching the patient's condition through regular physical exams and blood tests, but not giving treatment unless there are changes in test results. It can be a practical alternative to treatment in localized prostate cancer. Hypogonadal men have low testosterone associated with symptoms such as low libido and erectile problems. TRT can be used to treat hypogonadism by increasing testosterone levels, which may improve associated symptoms. TRT is often not used in men with prostate cancer due to concerns it may lead to the cancer growing or spreading. This may lead hypogonadal men to have a poor quality of life or to discontinue AS. TRT may improve treatment and quality of life outcomes in hypogonadal men with localized prostate cancer on active surveillance.

开始日期2025-01-01

申办/合作机构

Roswell Park Comprehensive Cancer Center

RBR-8xtsgvv / Not yet recruitingN/AIIT

Evaluation of Metabolic, Inflammatory, Cardiovascular and Endothelial Risk markers in transgender men on Testosterone therapy

开始日期2024-12-15

申办/合作机构-

100 项与睾酮相关的临床结果

登录后查看更多信息

100 项与睾酮相关的转化医学

登录后查看更多信息

100 项与睾酮相关的专利（医药）

登录后查看更多信息

61,728

项与睾酮相关的文献（医药）

2025-05-01·Journal of Environmental Sciences

The effects of 17β-trenbolone and bisphenol A on sexual behavior and social dominance via the hypothalamic-pituitary-gonadal axis in male mice

Article

作者: Sun, Minghe ; Luan, Jialu ; Zhao, Qili ; Zhang, Shuhui ; Feng, Xizeng ; Bai, Huijuan ; Sun, Mingzhu ; Zhao, Xin ; Yu, Qian ; Fu, Zhenhua ; Zuo, Xiang

17β-Trenbolone (17-TB) is well documented as an environmental endocrine disruptor in aquatic biological studies, but its effects on mammals remain poorly understood. Furthermore, 17-TB acts as a hormone with properties similar to testosterone, and the consequences of juvenile exposure on adult social behavior remain uncertain. Bisphenol A (BPA) acts as an estrogen-like hormone, compared to 17-TB. Three-week-old male Balb/c mice were exposed orally to 17-TB (100 µg/(kg·day)) and BPA (4 mg/(kg·day)) for 28 days. Assessments of social interactions and a three-chamber test showed that 17-TB increased virility in male mice, intensified both male and female sexual behavior, and attracted and accepted female mice. It also increased social dominance through tube tests in male mice and markedly activated the c-Fos⁺ immune response in the medial prefrontal cortex (mPFC) and basal amygdala (BLA). ELISA data showed that 17-TB and BPA exposure significantly affected serum gonadotropin-releasing hormone (GnRH), growth hormone (GH), estradiol (E2), and luteinizing hormone (LH) levels, as well as testicular lesions and androgen receptor (ARβ) and estrogen receptor (ERα) synthesis. Testicular transcriptomic analysis further confirmed that could disrupt steroid synthesis and linoleic acid-related biometabolic processes. These findings suggest the influence of 17-TB and BPA exposure on sexual behavior and fertility in male mice, possibly through modulation of the hypothalamic-pituitary-gonadal axis. This study provides insights relevant to human reproductive health and neuro-social behavioral research, and the potential risk of environmental disturbances should not be overlooked.

2025-03-01·Journal of Orthopaedics

Geographical incidence of testosterone supplementation in total hip and knee arthroplasty

Article

作者: Kuznetsov, Mikhail ; Smith, Eric L ; Coden, Gloria ; Grant, Andrew ; Smith, Eric L.

Introduction:

Prescription testosterone usage in the United States declined after 2013 following reports of its association with myocardial infarction and stroke. However, more recently there has been a documented increase in testosterone prescriptions. Recently, testosterone levels have also been hypothesized to increase infection risk in patients undergoing elective shoulder arthroplasty. Furthermore, testosterone may increase the risk of venous thromboembolism. These complications are perioperative concerns for total hip and knee arthroplasties (THA/TKA). Therefore, the purpose of our study is to identify trends in the incidence of testosterone prescriptions in patients who underwent THA/TKA with respect to geographical population data.

Methods:

We retrospectively reviewed 40,711 primary THAs and 50,893 primary TKAs performed in males between 1/1/2016 and 12/31/2021 using a commercial claims database. Records were reviewed for demographics, geographical location, and supplemental testosterone prescriptions within 1 year prior to surgery. Patient Metropolitan Statistical Area (MSA) was assessed with respect to United States Census Population Data.

Results:

We identified 91,604 males who underwent primary THA (n = 40,711) or TKA (n = 50,893). For THA/TKA, patients who were younger had a higher likelihood of having a supplemental testosterone prescription (OR = 0.99, 95 % CI [0.99-1.00], p < 0.001). TKA patients (2,507, 4.9 %) had a higher rate of testosterone prescriptions than THA patients overall (1,413, 3.4 %), (OR = 1.44 95 % CI [1.35, 1.54], p < 0.001) as well as within each year.For THA and TKA patients, patients in the Midwest (OR = 1.61, p < 0.001), South (OR = 3.04, p < 0.001), and West (OR = 2.28, p < 0.001) regions all had higher testosterone prescription rates than the Northeast. Patients living in a city (MSA population ≥200,000) were more likely to be prescribed testosterone (OR = 1.20, p = 0.002).

Conclusion:

Surgeons conducting TKA/THA should be aware that younger patients, those in higher population areas, and those in the Midwest, South, and West regions are more likely to be prescribed testosterone than those in the Northeast.

2025-02-01·NEUROCHEMICAL RESEARCH

Lactobacillus Helveticus Improves Controlled Cortical Impact Injury-Generated Neurological Aberrations by Remodeling of Gut-Brain Axis Mediators

Article

作者: Pasam, Tulasi ; Dandekar, Manoj P. ; Dandekar, Manoj P ; Padhy, Hara Prasad

Considerable studies augured the potential of gut microbiota-based interventions in brain injury-associated complications. Based on our earlier study results, we envisaged the sex-specific neuroprotective effect of Lactobacillus helveticus by remodeling of gut-brain axis. In this study, we investigated the effect of L. helveticus on neurological complications in a mouse model of controlled cortical impact (CCI). Adult, male and female, C57BL/6 mice underwent CCI surgery and received L. helveticus treatment for six weeks. Sensorimotor function was evaluated via neurological severity score and rotarod test. Long-term effects on anxiety-like behavior and cognition were assessed using the elevated-zero maze (EZM) and novel object recognition test (NORT). Brain perilesional area, blood, colon, and fecal samples were collected post-CCI for molecular biology analysis. CCI-operated mice displayed significant neurological impairments at 1-, 3-, 5-, and 7-days post-injury (dpi) and exhibited altered behavior in EZM and NORT compared to sham-operated mice. However, these behavioral changes were ameliorated in mice receiving L. helveticus. GFAP, Iba-1, TNF-α, and IL-1β expressions and corticotrophin-releasing hormone (CRH) levels were elevated in the perilesional cortex of CCI-operated male/female mice. These elevated biomarkers and decreased BDNF levels in both male/female mice were modified by L. helveticus treatment. Additionally, L. helveticus treatment restored altered short-chain fatty acids (SCFAs) levels in fecal samples and improved intestinal integrity but did not affect decreased plasma levels of progesterone and testosterone in CCI mice. These results indicate that L. helveticus exerts beneficial effects in the CCI mouse model by mitigating inflammation and remodeling of gut microbiota-brain mediators.

233

项与睾酮相关的新闻（医药）

2024-12-12

·PRNewswire

AZURITY PHARMACEUTICALS, INC. ANNOUNCES AVAILABILITY OF AZMIRO™ (testosterone cypionate) injection for intramuscular use, CIII

WOBURN, Mass., Dec. 12, 2024 /PRNewswire/ -- Azurity Pharmaceuticals announced today the availability of Azmiro™, the first and only FDA-approved prefilled testosterone cypionate injection. Azmiro is an androgen indicated for testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone. "Azurity's purpose is to serve overlooked patients by developing innovative dose forms and formulations to serve unmet needs," said Richard Blackburn, CEO of Azurity Pharmaceuticals. "The commercial availability of Azmiro offers a convenient prefilled option for healthcare providers administering testosterone to patients." Testosterone cypionate intramuscular injections are commonly used as a testosterone replacement therapy for patients with low testosterone by drawing up testosterone cypionate doses from a vial, then administering with a syringe. Azmiro provides an FDA-approved prefilled option now available as a 200 mg/mL single dose syringe. Safety and efficacy of Azmiro in men with age-related hypogonadism have not been established. For full Azmiro prescribing information, including medication guide, please go to azmiro.com. About Azurity Pharmaceuticals, Inc. Azurity specializes in providing innovative, high-quality medicines that serve overlooked patients. We supply a large number of products to treat a wide range of medical conditions. These include anti-infective, cardiovascular/cardiology, central nervous system/cerebrovascular, endocrinology, gastrointestinal, immunology, and oncology medicines. Many of our medicines are dose-form innovations for patients with needs that are not met by other available products. Our medicines have benefited millions of people. For more information, visit . PP-AZO-US-0033 SOURCE Azurity Pharmaceuticals, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

上市批准

2024-12-05

·生物谷

睾酮是求偶的催化剂，但却不是欲望开关？！PRSBBS | 男性的性欲程度与其每日的睾酮水平并无直接关联

睾酮（testosterone）在许多物种的生殖行为中扮演着重要角色。虽然科学家们普遍认为睾酮能够调节人类的性欲波动，但直接证据却少之又少。近日，一篇发表在国际杂志Proceedings of the Royal Society B: Biological Sciences上题为“Day-to-day associations between testosterone, sexual desire and courtship efforts in young men”的研究报告中，来自加利福尼亚大学等机构的科学家们通过研究发现，男性的性欲程度或许与其机体每日睾酮的水平并无关联。在这项研究中，来自加利福尼亚大学等机构的研究人员收集了41名成年男性志愿者在31天内的唾液样本，并让这些参与者每天记录他们的性欲水平以及与求爱、约会或性关系相关的其他想法。这项研究旨在探索睾酮水平是否真的能驱动男性的性欲。观察到以受试者为中心的机体睾酮水平与性欲之间的关系长期以来，人们普遍认为，当男性体内的睾酮水平上升时，他们会感到更强的性欲。毕竟，睾酮常常被视为阳刚之气的象征，这种观点似乎合情合理。然而，这项研究的结果却出乎意料。研究人员发现，某一天的睾酮水平与当天的性欲之间并没有明显的关联。换句话说，即使睾酮水平升高，男性的性欲也不一定会随之增强。这就像一个水龙头，即使开得再大，水流也不一定会变得更急。不过，研究确实发现了一些有趣的差异。单身男性在睾酮水平较高的日子里，往往会更加积极地进行求爱行为。这表明，睾酮可能更多地影响了男性的求偶行为，而不是单纯的性欲。用一个比喻来说，睾酮更像是一个“求偶助推器”，而不是“欲望开关”。此外，研究还指出，睾酮水平通常会因日常活动而波动，比如性行为、疲劳程度甚至是饮食。这些活动对睾酮的影响可能需要三天时间才能显现出来。因此，研究人员在分析数据时考虑了这一点。综上所述，这项研究提供了关于睾酮和性欲之间日常关联的新数据，并表明，当睾酮水平超过某个最低阈值时，它并不会进一步增加性欲。相反，睾酮似乎在促进求偶行为方面发挥着更重要的作用。这为理解睾酮在人类进化中的功能提供了一个新的视角。参考文献： Tikal Catena, Blair T. Crewther, Adar B. Eisenbruch, et al. Day-to-day associations between testosterone, sexual desire and courtship efforts in young men, Proceedings of the Royal Society B: Biological Sciences (2024). DOI:10.1098/rspb.2024.1508 本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！点击下方「阅读原文」，前往生物谷官网查询更多生物相关资讯~

2024-12-03

·GlobeNewswire-Health Care

KYZATREX® (testosterone undecanoate) CIII Capsules EXPANDS DISTRIBUTION THROUGH NEW COLLABORATION WITH GAMEDAY MEN’S HEALTH

The Deal Gives Gameday Men’s Health Patients Access to The FDA-Approved Oral Testosterone Therapy At 250+ Health Centers RALEIGH, N.C., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Gameday Men’s Health, the leader in men’s health clinics nationwide, today announced it is expanding its testosterone therapy options to include KYZATREX® (testosterone undecanoate) CIII capsules. Partnering with Marius Pharmaceuticals, Gameday Men’s Health now provides access to FDA-approved KYZATREX, a prescription medication for adult men who have low or no testosterone due to certain medical conditions, in all Gameday Men’s Health centers across 48 states. KYZATREX is available in an oral form, providing a non-invasive and convenient alternative to traditional injection-based methods. Gameday Men’s Health is a pioneering health clinic designed to help men reclaim their lives by optimizing four common areas of male concern - low testosterone, erectile dysfunction and enhancement, weight loss, and vitamin therapy. With in-house labs, expert medical teams, and personalized treatment plans, Gameday delivers discreet, effective solutions to support men’s optimal health and vitality. Shalin Shah, CEO of Marius Pharmaceuticals, says, “Given the staggering numbers of testosterone deficient men across the country, we are glad to see KYZATREX offered at one of the most rapidly growing men’s clinics. It is critical that we normalize this critical, metabolic therapy so men feel comfortable getting the care that they need and glad to see Gameday solving this issue.” The launch of KYZATREX at Gameday Men’s Health comes at a time when testosterone deficiency is a rising global epidemic as it affects approximately four in 10 men older than 45 years and 30-50% of men with obesity or type 2 diabetes, according to the Endocrine Society (2022). Testosterone deficiency is bi-directional with metabolic diseases and early research indicates a role in further conditions such as depression and inflammatory diseases. While TRT has traditionally consisted of injections, implanted pellets, patches, or gels, KYZATREX instead delivers testosterone through a twice-daily, softgel capsule that is safe and convenient. The oral delivery excludes the administration pain, mess, transference risk to others around you, and changes to eating habits which can occur with other TRT delivery systems. KYZATREX is primarily absorbed via the lymphatic system, effectively bypassing the liver and avoiding toxicity. “Our goal has always been to make men's health accessible and adaptable. Oral TRT provides men with a choice in TRT that aligns with their preferences, allowing them to feel their best with minimal interruption to their daily lives,” said Evan Miller, CEO and Founder of Gameday Men’s Health. For more information about Gameday Men’s Health visit gamedaymenshealth.com. For more information about KYZATREX, visit www.kyzatrex.com, and for more information about Marius Pharmaceuticals, visit www.mariuspharma.com. About Marius Pharmaceuticals Marius Pharmaceuticals strives to better the lives of patients by focusing on therapies designed for hypogonadism or Testosterone Deficiency. The company's vision is to holistically improve metabolic health and mitigate significant unnecessary costs to the global healthcare system. For more information, please visit www.mariuspharma.com. About Gameday Men’s HealthGameday Men's Health is a premier men’s health clinic offering a range of services, including testosterone replacement therapy, erectile dysfunction treatment, weight loss programs, and vitamin therapy. Founded in 2018, this franchise is designed to help men transform their lives with a simple, three-step signature process: testing, proprietary wellness plans, and personalized treatment sessions. For more information, please visit www.gamedaymenshealth.com About KYZATREX® (testosterone undecanoate)KYZATREX is a proprietary softgel oral formulation absorbed primarily via the lymphatic system (meaning it is not toxic to the liver) and indicated in adult males for conditions associated with a deficiency or absence of endogenous testosterone. The safety and efficacy of KYZATREX was demonstrated in a phase 3, multi-center, open-label, six-month study in 155 hypogonadal males between 18 and 65 years of age with documented hypogonadism, as defined by a below normal serum testosterone level (≤281 ng/dL) and at least one sign or symptom of testosterone deficiency. In the efficacy population (n=139), 88 percent of hypogonadal men treated with KYZATREX achieved a mean plasma total testosterone concentration (Cavg) over 24 hours within the normal range (222-800 ng/dL) on the final pharmacokinetic (PK) visit of the study at Day 90 (primary endpoint). Based on exploratory endpoints, patients who received KYZATREX reported improvements in symptoms of low testosterone, including quality of life, energy/fatigue, erectile function, sexual intercourse, and mood. The most common side effect reported in ≥2 percent of KYZATREX patients was increased blood pressure (2.6%). The safety and efficacy of KYZATREX in males less than 18 years old have not been established. Please see additional Important Safety Information for KYZATREX below, including Boxed Warning for potential increased blood pressure, or visit www.kyzatrex.com.Important Safety Information for KYZATREX® (Testosterone Undecanoate Capsules)UseKYZATREX® (testosterone undecanoate) is a prescription drug that is used to treat adult men who have low or no testosterone levels due to certain medical conditions. KYZATREX is a controlled substance (CIII) because it contains testosterone. It is not known if KYZATREX is safe or effective in males younger than 18 years old. Improper use may affect bone growth in children. KYZATREX is not meant for use by women. Important Safety Information for KYZATREX® KYZATREX can increase blood pressure, which can increase the risk of having a heart attack or stroke and can increase risk of death due to a heart attack or stroke. Your risk may be greater if you have already had a heart attack or stroke or if you have other risk factors for heart attack or stroke. If your blood pressure increases while on KYZATREX, blood pressure medicines may need to be started. If you are currently taking blood pressure medicines, they may need to be changed or new blood pressure medicines may need to be added to control your blood pressure.If your blood pressure cannot be controlled, KYZATREX may need to be stopped.Your healthcare provider will monitor your blood pressure while you are being treated with KYZATREX. Do not take KYZATREX if you: have breast cancer; have or might have prostate cancer; are a woman who is pregnant (KYZATREX may harm your unborn baby); are allergic to KYZATREX or any of its ingredients; or have low testosterone without certain medical conditions (e.g., do not take KYZATREX if you have low testosterone due to age). Before you take KYZATREX, tell your healthcare provider about all of your medical conditions, including if you: have high blood pressure or are treated for high blood pressure; have a history of diabetes; have heart problems; have high red blood cell count (hematocrit) or high hemoglobin laboratory value; have urinary problems due to an enlarged prostate; have liver or kidney problems; or have problems breathing while you sleep (sleep apnea). Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking KYZATREX with certain other medicines can affect each other. Especially, tell your healthcare provider if you take: insulin; medicines that decrease blood clotting (blood thinners); corticosteroids; or medicines that increase blood pressure, such as some cold medicine and pain medicines. KYZATREX may cause other serious side effects including: Increase in red blood cell count (hematocrit) or hemoglobin, which can increase the risk of blood clots, strokes, and heart attacks. You may need to stop KYZATREX if your red blood cell count increases.If you already have an enlarged prostate, your signs and symptoms may worsen while taking KYZATREX. These may include: increased urination at night; trouble starting your urine stream; urinating many times during the day; urge to go to the bathroom right away; a urine accident; inability to pass urine or weak urine flow.Increased risk of prostate cancer.Blood clots in the legs or lungs. Signs and symptoms of a blood clot in your leg can include pain, swelling or redness. Signs and symptoms of a blood clot in your lungs can include difficulty breathing or chest pain.Abuse. Testosterone can be abused when taken at higher than prescribed doses and when used with other anabolic androgenic steroids. Abuse can cause serious heart and psychological side effects.In large doses, KYZATREX may lower your sperm count.Liver problems. Symptoms of liver problems may include: nausea or vomiting; yellowing of your skin or whites of your eyes; dark urine; pain on the right side of your stomach area (abdominal pain).Swelling of your ankles, feet, or body (edema), with or without heart failure.Enlarged or painful breasts.Breathing problems while you sleep (sleep apnea). Call your healthcare provider right away if you have any of the serious side effects listed above. The most common side effect of KYZATREX is high blood pressure. Other side effects may include: headache, joint or back pain, diarrhea, increased red blood cell count, anxiety, constipation, swelling of the legs, and increased prostate specific antigen (PSA) levels. These are not all the possible side effects of KYZATREX. For more information, ask your healthcare provider or pharmacist. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088. You may also report side effects to Marius [by visiting www.mariuspharma.com]. Keep KYZATREX and all medicines out of the reach of children. See Full Prescribing Information and Medication Guide for KYZATREX. Media Contact:Marius PharmaceuticalsLilly Washburn lilly@mariuspharma.com A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/3da5b291-b193-4057-9ec7-7e72839cddd9

临床结果临床3期上市批准

100 项与睾酮相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00075	睾酮	G03BA03	DB00624

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
继发性睾丸衰竭	美国	Endo Operations Ltd.	2010-12-29
心理性性功能障碍	欧盟	Warner Chilcott Ltd.	2006-07-28
心理性性功能障碍	欧盟	Teva NI Ltd.	2006-07-28
心理性性功能障碍	冰岛	Warner Chilcott Ltd.	2006-07-28
心理性性功能障碍	冰岛	Teva NI Ltd.	2006-07-28
心理性性功能障碍	列支敦士登	Warner Chilcott Ltd.	2006-07-28
心理性性功能障碍	列支敦士登	Teva NI Ltd.	2006-07-28
心理性性功能障碍	挪威	Teva NI Ltd.	2006-07-28
心理性性功能障碍	挪威	Warner Chilcott Ltd.	2006-07-28
低睾酮水平	美国	Endo Operations Ltd.	2002-10-31
睾酮缺乏	澳大利亚	Teva Pharmaceuticals Australia Pty Ltd	2002-04-10
性腺机能减退	美国	AbbVie, Inc.	1995-09-29

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
先天性睾丸发育不全综合征	临床3期	美国	Amneal Intermediate, Inc.	2014-03-01
关节痛	临床3期	美国	National Cancer Institute	2013-08-01
关节痛	临床3期	波多黎各	National Cancer Institute	2013-08-01
乳腺癌	临床3期	美国	National Cancer Institute	2013-08-01
乳腺癌	临床3期	波多黎各	National Cancer Institute	2013-08-01
潮热	临床3期	美国	National Cancer Institute	2013-08-01
潮热	临床3期	波多黎各	National Cancer Institute	2013-08-01
肌肉骨骼畸形	临床3期	美国	National Cancer Institute	2013-08-01
肌肉骨骼畸形	临床3期	波多黎各	National Cancer Institute	2013-08-01
阿尔茨海默症	临床3期	美国	Solvay Pharmaceuticals, Inc.	2009-07-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


UEGW	N/A	原发性恶性肝肿瘤 testosterone \| estradiol \| tumor necrosis factor receptor superfamily member 9 (TNFRS9) ... 更多	-	TESTOSTERONE (Estradiol levels)	範膚壓襯觸範餘膚膚範(鑰艱觸壓夢膚鬱憲獵襯) = 夢淵糧廠遞鹽蓋夢願壓選顧糧範衊願製艱選廠 (醖獵廠壓鏇鑰簾襯鑰淵 ) 更多	积极	2024-10-13
SFN2024	N/A	-	-	Testosterone-treated female X. laevis	衊積餘觸醖齋蓋憲憲顧(觸廠築廠鬱築築衊淵夢) = the quantity of PNNs in testosterone-treated, fully masculinized female brains was similar to those of sham-operated female brains 糧顧簾鹹選觸選鹽蓋膚 (憲艱糧鬱顧觸繭觸遞憲 )	-	2024-10-07
				testosterone (Sham-operated female X. laevis)
NCT05781685 (CTgov)	早期临床1期	急性疼痛	20	Testosterone+Placebo Syrup (Testosterone)	餘艱衊淵製憲衊願簾憲(網積簾憲範繭淵夢淵鑰) = 願醖壓鏇蓋淵淵範壓齋遞壓廠餘壓淵繭窪繭襯 (顧壓選衊築糧艱遞顧鹹, 鬱醖網淵觸遞鏇鑰積糧 ~ 繭衊獵鏇衊膚顧淵糧鑰) 更多	-	2024-08-05
				Testosterone+Placebo Syrup (Placebo)	餘艱衊淵製憲衊願簾憲(網積簾憲範繭淵夢淵鑰) = 顧壓餘築積鑰遞範網願遞壓廠餘壓淵繭窪繭襯 (顧壓選衊築糧艱遞顧鹹, 淵壓觸範壓網襯顧鬱遞 ~ 願範齋壓願築鏇鬱觸鑰) 更多
ADA2024	N/A	肥胖	-	Testosterone Replacement Therapy (TRT)	鹽遞遞齋糧獵構齋艱艱(齋鏇繭鏇齋觸範廠鏇顧) = 鹽鏇顧廠遞憲遞繭齋獵繭鬱窪醖選餘製顧獵艱 (醖齋蓋觸鏇鏇願積遞窪 ) 更多	-	2024-06-14
ATS2024	N/A	急性肺损伤	-	Anabolic Testosterone Isocaproate	鹽鑰蓋構憲構鹽艱製製(壓夢襯廠繭選選築簾夢) = Our patient is a 46-year-old smoker who presented with two days of progressively dyspnea preceded by two weeks of cough. His history was significant for polysubstance use disorder. In the emergency department, he was found to be hypoxic to 60% with diffuse crackles and expiratory wheezes on exam, so he was given a dose of systemic steroids and started nebulizers. Chest radiograph and chest CT scan (figure 1) showed diffuse bilateral ground glass opacities. His respiratory status deteriorated rapidly, and he was intubated, then he was ultimately admitted to the MICU for acute hypoxemic respiratory failure. All infectious work-up including sputum culture and rapid respiratory pathogen PCR were negative. Over the next three days, he continued to have higher oxygen requirements, so empiric steroids were given then flexible bronchoscopy was performed with BAL demonstrating eosinophils of 14%, and lymphocytes of 3%. BAL bacterial and fungal cultures were negative. He was started on IV methylprednisolone, responded very well and after 3 days he was extubated. Following extubation, he reported using non-prescribed anabolic testosterone isocaproate for bodybuilding over the past several months and had three similar presentations with respiratory distress with chest CT also showing bilateral ground glass opacities and negative infectious workup. In all of them, he exhibited clinical improvement following each of these presentations with normal chest radiographs in between. He was followed in pulmonary clinic and was advised to stop using anabolic steroids with no recurrence to date. 齋顧構選鬱鹹廠觸繭積 (顧積構範構製構顧鹽簾 )	-	2024-05-19
ISN WCN2024	N/A	梗塞	-	Rivaroxaban 15mg/day	簾蓋選顧願範壓遞積鬱(襯範願膚簾鹹醖構窪遞) = 襯選築餘顧鹹鬱製積鏇憲鑰鬱膚齋窪製鬱願網 (襯製糧憲鏇壓製淵鹽淵 )	-	2024-04-01
NCT03518034 (TRAVERSE, CTgov)	临床4期	性腺机能减退 \| 心血管疾病	5,246	AndroGel® (AndroGel 1.62%)	齋廠簾衊齋觸憲壓膚糧(網製鬱鏇鏇憲鏇淵淵鏇) = 網衊襯衊遞繭遞積齋選獵鹹糧鏇顧顧壓醖餘築 (鏇蓋憲構蓋範衊糧艱衊, 獵構醖鑰遞鑰淵繭襯廠 ~ 衊繭顧艱齋窪獵襯憲願) 更多	-	2024-03-13
				Placebo (Placebo)	齋廠簾衊齋觸憲壓膚糧(網製鬱鏇鏇憲鏇淵淵鏇) = 網遞醖蓋壓遞廠艱選製獵鹹糧鏇顧顧壓醖餘築 (鏇蓋憲構蓋範衊糧艱衊, 夢襯簾淵選醖憲願醖網 ~ 糧鏇鹽鑰餘網鏇網齋願) 更多
NCT00467987 (CTgov)	N/A	2型糖尿病 \| 继发性睾丸衰竭 \| 动脉粥样硬化 ... 更多	47	androgel (Androgel)	願遞壓鏇廠齋醖簾網願(獵鹽構壓獵鹹壓衊遞顧) = 鏇鹽壓築繭顧壓網觸糧糧範鏇餘淵蓋窪窪餘齋 (積艱襯顧夢獵簾願製廠, 鏇鹹醖積鹹築膚襯選網 ~ 餘夢顧積淵繭襯製餘繭) 更多	-	2024-02-06
				placebo (Placebo)	願遞壓鏇廠齋醖簾網願(獵鹽構壓獵鹹壓衊遞顧) = 觸築憲艱醖製顧顧鏇築糧範鏇餘淵蓋窪窪餘齋 (積艱襯顧夢獵簾願製廠, 廠蓋製範鬱築蓋製築選 ~ 鬱窪繭齋憲蓋選壓製鏇) 更多
NCT03518034 (TRAVERSE, Pubmed \| Br Dent J \| N Engl J Med) 人工标引	临床4期	性腺机能减退	5,204	Testosterone gel	憲簾觸鏇淵網顧糧蓋築(構蓋願製觸膚膚觸願選) = 艱壓積鏇襯構鹹遞鏇窪繭窪襯簾觸構築願積衊 (窪網壓顧餘觸衊憲築構 )	不佳	2024-01-18
				Placebo gel	憲簾觸鏇淵網顧糧蓋築(構蓋願製觸膚膚觸願選) = 壓簾製鹽積鹹壓蓋築獵繭窪襯簾觸構築願積衊 (窪網壓顧餘觸衊憲築構 )
NCT04439799 (CTgov)	临床4期	无睾症	81	Testosterone Cypionate 200 Mg/ML (Testosterone Cypionate Group)	構餘艱選鑰築餘壓製醖(遞網簾艱蓋衊範醖構衊) = 鬱遞鑰夢範網鬱鹹窪願窪願簾構淵築膚壓齋窪 (選衊膚壓膚壓淵膚鹽艱, 繭築製衊淵襯獵襯餘糧 ~ 夢願網窪齋壓遞餘衊艱) 更多	-	2023-12-13
				Intranasal Testosterone (Natesto Group)	構餘艱選鑰築餘壓製醖(遞網簾艱蓋衊範醖構衊) = 餘網鹹廠積膚膚蓋鑰構窪願簾構淵築膚壓齋窪 (選衊膚壓膚壓淵膚鹽艱, 顧繭艱獵鹹淵選製膚廠 ~ 鹽糧遞願範網積繭鹽願) 更多